Allergan
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Allergan sits in the top decile of US sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count).
Allergan: 314 sponsored US clinical trials, none currently recruiting.
Allergan sponsors 314 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 278 completed. 142 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ocular Hypertension, with 9 trials.
Top-decile sponsor footprint
Allergan ranks in the top decile of sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
278 of 313 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
314 total, page 7 of 7
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
NCT00076687
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
NCT00652106
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
NCT00652483
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
NCT00332059
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
NCT00651729
NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Access Post-Approval Study
NCT01853605
Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00651859
Research Study in Patients With Persistent Macular Edema
NCT00035906
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension
NCT00332072
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
NCT00332540
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
NCT00025818
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
NCT00332384
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
NCT00332436
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
NCT00332345
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 85 |
| Phase 3 | 91 |
| Phase 4 | 51 |
Therapeutic Areas
How the Allergan archive is shaped
314 indexed studies, none listed as recruiting (0% open); 278 completed (89%).
Phase mix: 142 late (III/IV) vs 114 early (I/II) (balanced across stages).
Top condition: Ocular Hypertension (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Allergan: archived-pipeline peers nationwide
Peers matched on 314 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Allergan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 314 archived trials
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
- Celgene · 308 trials · 4% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Allergan page
314 registered trials is a research-attention snapshot, not an endorsement of Allergan or any single study.
- None of Allergan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ocular Hypertension is the condition Allergan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Allergan pipeline card: 314 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.